

29. Use according to any of Claims 25 to 28 for combating toxicity in an individual who has one or more clinical symptoms of toxicity caused by the antifolate compound.

5 30. Use according to Claim 29 wherein the clinical symptom of toxicity caused by the antifolate compound is selected from anaemia, anorexia, asthenia, dehydration, diarrhoea, fatigue, fever, hepatotoxicity, hyperbilirubinaemia, leukopaenia, mucositis, myelosuppression, nausea, neutropaenia, rash, reversible transaminitis, stomatitis, thrombocytopaenia and vomiting.

10 31. Use of an antifolate compound of Formula I as defined in Claim 1 or Claim 2 in the preparation of a medicament for combating a disease combatable by said antifolate compound in an individual who is subsequently administered an enzyme that has carboxypeptidase G activity.

15 32. 30. Use according to any of Claims 25 to 31 for combating toxicity in an individual who is administered a folate pathway rescue agent.

32. 33. Use according to Claim 32 wherein the individual is administered the folate pathway rescue agent prior to the enzyme that has carboxypeptidase G activity.

33. 34. Use according to Claim 32 wherein the individual is administered the folate pathway rescue agent after the enzyme that has carboxypeptidase G activity.

25 34. 35. Use according to Claim 32 wherein the individual is administered the folate pathway rescue agent and the enzyme that has carboxypeptidase G activity substantially simultaneously.

30 35. 36. Use of a folate pathway rescue agent in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined

in Claim 1 or Claim 2 in an individual who is administered an enzyme that has carboxypeptidase G activity.

36. 37. Use of an enzyme that has carboxypeptidase G activity and a folate pathway rescue agent in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined in Claim 1 or Claim 2.

37. 38. Use according to any of Claims 32 to 37 wherein the antifolate compound is an inhibitor of DHFR or GARFT, and the folate pathway rescue agent is 10 leucovorin.

38. 39. Use according to Claim 38 wherein the antifolate compound is LY309887, AG2034, or AG2037.

15 39. 40. Use according to any of Claims 32 to 37 wherein the antifolate compound of Formula I is an inhibitor of TS, and the folate pathway rescue agent is thymidine.

40. 41. Use according to Claim 40 wherein the antifolate compound of Formula I 20 is Tomudex.

41. 42. Use according to any of Claims 28 to 41 wherein the enzyme that has carboxypeptidase G activity is at a dose of about 50 Units per kg body weight.

25 42. 43. Use according to any of Claims 25 to 42 for combating toxicity caused by an antifolate compound of Formula I in an individual who is being treated for a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease by administration of the antifolate compound.

30 43. 44. Use of an antifolate compound of Formula I as defined in Claim 1 or Claim 2 in the preparation of a medicament for treating a condition selected from cancer,

RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease in an individual who is subsequently administered an enzyme that has carboxypeptidase G activity.

5 44.48. Use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for complementing the therapy of a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease that is being treated by administration of an antifolate compound of Formula I, *wherein the medicament is for combating toxicity caused by the antifolate compound of Formula I.*

10 45.46. Use according to any of Claims 43 to 46 wherein the antifolate compound of Formula I and the cancer to be treated are as defined in any of Claims 21-24.

46.47. A therapeutic system comprising an antifolate compound of Formula I as defined above in Claim 1 or 2, and an enzyme that has carboxypeptidase G activity.

47.48. A therapeutic system according to Claim 47 further comprising a folate pathway rescue agent.

20 48.49. An *ex vivo* method of cleaving a terminal L-glutamate moiety from a compound of Formula I as defined in Claim 1 or Claim 2, the method comprising contacting the compound with an enzyme that has carboxypeptidase G activity.

49.50. A method of determining the rate and/or extent of cleavage of a compound of Formula I as defined in Claim 1 or Claim 2 by an enzyme that has carboxypeptidase G activity, the method comprising:

providing the compound of Formula I,
contacting the compound of Formula I with an enzyme that has carboxypeptidase G activity under conditions such that cleavage of the compound can occur, and

monitoring the rate and/or extent of cleavage of the compound of Formula I over time.

50. ⁴⁹ 51. A method according to Claim 50 wherein the monitoring step comprises monitoring the amount and/or concentration of the compound of Formula I.

51. ⁴⁹ 52. A method according to Claim 50 or 51 wherein the monitoring step comprises monitoring the amount and/or concentration of one or more break-down products of the compound of Formula I.


52. ⁴⁹ 53. A method according to any of Claims 50 to 52 which is performed *ex vivo*.

53. ⁴⁹ 54. A method according to any of Claims 50 to 53 which is performed *in vivo*.

15 54. ⁵³ 55. A method according to Claim 54 further comprising determining whether an additional dose of the enzyme that has carboxypeptidase G activity is required in order reduce the amount of the compound of Formula I to a predetermined level.

20 55. ⁵³ 56. A method according to Claim 54 or 55 further comprising contacting the compound of Formula I with an additional dose of the enzyme that has carboxypeptidase G activity under conditions such that cleavage of the compound can occur.

25 56. ⁵⁷ A method of cleaving a compound comprising a structural fragment of Formula VIII,



wherein

the wavy line indicates the point of attachment of the structural fragment;

5 A⁶ represents O or S;

R⁸ represents H or one or two substituents selected from halo, C₁₋₄ alkyl and C₁₋₄ alkoxy;


10 R³ represents H or C₁₋₄ alkyl;

R⁴ represents -CH₂C(R^{9a})(R^{9b})-D;


R^{9a} and R^{9b} independently represent H or C₁₋₄ alkyl, or R^{9a} and R^{9b} together represent =C(H)R¹⁰;

15 R¹⁰ represents H or C₁₋₄ alkyl;

D represents C(O)OH, tetrazol-5-yl, (CH₂)₀₋₁-NHR¹¹, or, when R^{9a} and R^{9b} together represent =C(H)R¹⁰, then D may also represent H, or D represents a structural fragment of Formula IIIa or IIIb,



IIIa



IIIb

20

wherein the wavy lines indicate the point of attachment of the structural fragments;

R¹¹ represents H or C(O)R¹²;

25 R¹² represents H or phenyl substituted by C(O)OH and optionally substituted by one or two further substituents selected from halo, C₁₋₄ alkyl and C₁₋₄ alkoxy; and

alkyl, alkenyl and alkynyl groups, as well as the alkyl part of alkoxy groups, may be substituted by one or more halo atoms;

or a pharmaceutically acceptable salt and/or solvate thereof,

5

the method comprising contacting the compound comprising the structural fragment of Formula VIII with an enzyme that has carboxypeptidase G activity.

57. 58. A method according to Claim ⁵⁶ 57 that is performed *ex vivo*.

10

58. 59. A method according to Claim ⁵⁶ 57 that is performed *in vivo*.

59. 60. A method according to Claim ⁵⁶ 57 wherein the compound comprising the structural fragment of Formula VIII is an antifolate compound.

15

60. 61. A method according to Claim ⁵⁹ 60 for combating toxicity caused by the antifolate compound in an individual who has been administered the said antifolate compound in the course of medical treatment, or otherwise, the method comprising administering to the individual an enzyme that has carboxypeptidase G activity.

20

61. 62. Use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula VIII as defined in Claim ⁵⁷ 56.

25

62. 63. A method according to any of Claims 1 to 24 or ⁴⁸ 49 to ⁶⁰ 61, or a use according to any of Claims 25 to ⁴⁵ 46 or ⁶¹ 62, or a therapeutic system according to Claim ⁴⁶ 47 or ⁴⁸ 49, wherein the enzyme that has carboxypeptidase G activity is carboxypeptidase G₂, or a derivative thereof which has carboxypeptidase G activity.

30